Activation of aryl hydrocarbon receptor prolongs survival of fully mismatched cardiac allografts

Abstract

Recent data suggest that activation of aryl hydrocarbon receptor (AhR) by its high-affinity ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) results in expansion of regulatory T (Treg) cells and suppresses the development of autoimmune and allergic diseases in several models. Treg cells have been increasingly documented to suppress allograft rejection and even to establish stable long-term graft acceptance. However, the involvement of TCDD in the regulation of solid organ transplantation rejection is largely unknown. Here, we examined whether activation of AhR with TCDD altered cardiac allograft rejection in an allogeneic heart transplant model. Recipient C57BL/6 (H-2b) mice were administrated with a single intraperitoneal injection of TCDD, and the murine cardiac transplant models from BALB/c (H-2d) to C57BL/6 (H-2b) were built 24 h later. The complete cessation of cardiac contractility was defined as the observation endpoint. The effect of TCDD on T-cell proliferation was assessed by mixed lymphocyte reaction (MLR). Histological and immunohistochemical analyses were performed to estimate the severity of rejection. The phenotype and cytokine profile of lymphocytes were analyzed by flow cytometry and enzyme-linked immunosorbent assay (ELISA). Activation of AhR remarkably prolonged the survival of cardiac allografts to more than 20 days. In vitro, TCDD ugregulated the frequency of CD4+CD25+Foxp3+ Treg cells and suppressed the proliferation of T lymphocytes. In vivo, the prolonged survival time was associated with increased number of Treg cells in allografts and spleens. Furthermore, the secretion of interferon-γ (IFN-γ) and interleukin-17 (IL-17) was reduced to less than 50% of that of the PBS treatment control group by TCDD treatment, whereas IL-10 was elevated to 10-fold of that of the PBS treatment control group. Collectively, our data indicate that activation of AhR with a single dose of TCDD significantly prolonged the survival of fully allogeneic cardiac grafts, and the mechanism underlying this effect might be involved in the induction of Treg cells.

Keywords

aryl hydrocarbon receptor / 2,3,7,8-tetrachlorodibenzo-p-dioxin / cardiac transplantation / regulatory T cells / acute rejection

References

[1] SchmidtJV, BradfieldCA. Ah receptor signaling pathways. Annu Rev Cell Dev Biol, 1996, 12: 55-89

[2] SchmidtJV, SuGH, ReddyJK, et al.. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA, 1996, 93(13): 6731-6736

[3] SchmidtJV, CarverLA, BradfieldCA. Molecular characterization of the murine Ahr gene. Organization, promoter analysis, and chromosomal assignment. J Biol Chem, 1993, 268(29): 22 203-22 209

[4] KerkvlietNI, ShepherdDM, Baecher-SteppanL. T lymphocytes are direct, aryl hydrocarbon receptor (AhR)-dependent targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): AhR expression in both CD4+ and CD8+ T cells is necessary for full suppression of a cytotoxic T lymphocyte response by TCDD. Toxicol Appl Pharmacol, 2002, 185(2): 146-152

[5] QuintanaFJ, BassoAS, IglesiasAH, et al.. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature, 2008, 453(7191): 65-71

[6] GandhiR, KumarD, BurnsEJ, et al.. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol, 2010, 11(9): 846-853

[7] ApetohL, QuintanaFJ, PotC, et al.. The aryl hydrocar bon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol, 2010, 11(9): 854-861

[8] ZhangL, MaJ, TakeuchiM, et al.. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor. Invest Ophthalmol Vis Sci, 2010, 51(4): 2109-2117

[9] KerkvlietNI, SteppanLB, VorachekW, et al.. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy, 2009, 1(4): 539-547

[10] BankotiJ, RaseB, SimonesT, et al.. Functional and phenotypic effects of AhR activation in inflammatory dendritic cells. Toxicol Appl Pharmacol, 2010, 246(1–2): 18-28

[11] JuxB, KadowS, EsserC. Langerhans cell maturation and contact hypersensitivity are impaired in aryl hydrocarbon receptor-null mice. J Immunol, 2009, 182(11): 6709-6717

[12] MezrichJD, FechnerJH, ZhangX, et al.. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol, 2010, 185(6): 3190-3198

[13] VogelCF, GothSR, DongB, et al.. Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun, 2008, 375(3): 331-335

[14] ChenW, LiangX, PetersonAJ, et al.. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol, 2008, 181(8): 5396-5404

[15] MellorAL, MunnDH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol, 2004, 4(10): 762-774

[16] ShevachEM, DiPaoloRA, AnderssonJ, et al.. The lifestyle of naturally occurring CD4+CD25+Foxp3+ regulatory T cells. Immunol Rev, 2006, 212: 60-73

[17] SakaguchiS, OnoM, SetoguchiR, et al.. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev, 2006, 212: 8-27

[18] IzcueA, CoombesJL, PowrieF. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev, 2006, 212: 256-271

[19] BelkaidY, BlankRB, SuffiaI. Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol Rev, 2006, 212: 287-300

[20] RouseBT, SarangiPP, SuvasS. Regulatory T cells in virus infections. Immunol Rev, 2006, 212: 272-286

[21] AluvihareVR, KallikourdisM, BetzAG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol, 2004, 5(3): 266-271

[22] BeyerM, SchultzeJL. Regulatory T cells in cancer. Blood, 2006, 108(3): 804-811

[23] BenghiatFS, GracaL, BraunMY, et al.. Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. Transplantation, 2005, 79(6): 648-654

[24] FucsR, JesusJT, Souza JuniorPH, et al.. Frequency of natural regulatory CD4+CD25+ T lymphocytes determines the outcome of tolerance across fully mismatched MHC barrier through linked recognition of self and allogeneic stimuli. J Immunol, 2006, 176(4): 2324-2329

[25] LiW, KuhrCS, ZhengXX, et al.. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant, 2008, 8(8): 1639-1651

[26] MuthukumarT, DadhaniaD, DingR, et al.. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med, 2005, 353(22): 2342-2351

[27] JoffreO, SantolariaT, CaliseD, et al.. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med, 2008, 14(1): 88-92

[28] ChenZH. A technique of cervical heterotopic heart transplantation in mice. Transplantation, 1991, 52(6): 1099-1101

[29] VeldhoenM, HirotaK, WestendorfAM, et al.. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature, 2008, 453(7191): 106-109

[30] AllanSE, CromeSQ, CrellinNK, et al.. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol, 2007, 19(4): 345-354

[31] WangJ, Ioan-FacsinayA, van der VoortEI, et al.. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol, 2007, 37(1): 129-138

[32] AllanSE, PasseriniL, BacchettaR, et al.. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest, 2005, 115(11): 3276-3284

[33] TranDQ, RamseyH, ShevachEM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-β dependent but does not confer a regulatory phenotype. Blood, 2007, 110(8): 2983-2990

[34] BettelliE, CarrierY, GaoW, et al.. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006, 441(7090): 235-238

[35] GrouxH, O’GarraA, BiglerM, et al.. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997, 389(6652): 737-742